Immunome, Inc. Operating Lease Right-of-Use Assets
Immunome, Inc. (IMNM) had Operating Lease Right-of-Use Assets of $3.94 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Operating Lease, Right-of-Use Asset $3.94M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.83M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $2.98M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $3.13M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $3.94M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $2.83M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $2.98M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $3.13M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $3.27M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $4.16M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $4.28M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $2.39M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $2.52M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $1.46M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $1.56M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $345.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $174.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $230.00K 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $284.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $171.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $182.00K 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $190.00K 10-Q · filed 2022-05-12 | |
| 2022-01-01 | $500.00K 10-K · filed 2023-03-16 | $200.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |